

DAFTAR PUSTAKA

- Aaronson, Philip I & Jeremy P.T. Ward., 2008. *Sistem Kardiovaskular at a Glance*. London: Blackwell Publishing. Vol. 3 P. 11-33
- Ageno W., Gallus A.S., Wittkowsky A., Crowther, M., Hylek, E.M., Palareti, G., 2012. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. *Chest*. Vol. 141 No. 2 P. 44-88.
- Akhtar, R.P., Abid, A.R., Zafar, H., Khan, J.S., 2009. Risk upper gastrointestinal bleeding and perforation associated with low dose Aspirin as Plain and enteric coated formulations. *BMC Clin Pharmacol*. Vol. 1 No. 1 P. 1472-1478
- Alonso, A., Lopez, F.L., Matsushita, K., Loehr, L.R., Agarwal, S.K., Chen, L.Y., Soliman, E.Z., Astor, B.C., Coresh, J., 2011. Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation. *American Heart Association*. Vol. 123 P. 2946-2953
- Arboix, A. and Josefina, A., 2010. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. *Current Cardiology Reviews*. Vol. 6 No. 3 P. 150-161
- Baxter, Karen, 2010. *Stockley's Drug Interaction*. London, Chicago, Pharmaceutical Press. P. 56-286
- Berge, T., Lyngbakken, M.N., Hensen, H.I., Brynildsen, J., Pervez, M.O., Aagaard, T.V., Kvisvik, B., Christophersen, I.E., Steine, K., Ornland, T., Smith, P., Rosjo, H., Tveit, A., 2018. Prevalence of Atrial Fibrillation and Cardiovascular Risk Factors in a 63-65 Years Old General Population Cohort: The Akerhur Cardiac Examination (ACE) 1950 Study. *BMJ Open*. Vol. 8 P. 1-9

- Bungard, T.J., Yakiwchuk, E., Foisy, M., Brocklebank, C., 2011. Drug Interaction Involving Warfarin: Practice Tool and Practical Management Tips, *Canadian Pharmacists Journal*. Vol.144 No. 1 P. 21-25
- Camm A.J., Kirchhof, P., Lip, G.Y.H., Schotten, J., Savelieva, I., Ernst, S., Gelder, I.C.V., Al-Attar, N., Hird, G., Prendergast, B., Heidbuchel, H., *et al*, 2010. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart Journal*. P. 1-61
- Cavallari, L.H., Momary, K.M., Patel, S.R., Shapiro, N.L., Natuscu, E, Viana M.A.G., 2011. Pharmacogenomics of Warfarin Dose Requirements in Hispanics. *Blood Cell, Molecules, and Disease*. Vol. 46 P. 147-150
- Choi, K.H., Kim, A.J., Son, I.J., Kim, K.H., Kim, K.B., Ahn, H., and Lee, E.B., 2010. Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting. *J Korean Med Sci*. Vol. 25 No. 3 P. 337–341.
- Duraes, A. R., Carvalho, R. D., Muniz, J. Q. V., Fernandes, A. M. S., Roris, P. S., Aras, R., 2015. Warfarin Therapy: New Challenges of an Old Drug. *Journal of Hematology & Thromboembolic Disease*. Vol. 3 No. 3 P. 1-3
- Donald, M.M., Au, N.T., Wittkowsky, A.K., Rettie, A.E., 2012. Warfarin-Amiodarone Drug-Drug Interactions: Determination of $[I]_u / K_{I,u}$ for Amiodarone and Its Plasma Metabolites. *Clinical Pharmacology & Therapeutics*. Vol. 91 No. 4 P. 709-717

- Douketis, J. D., 2011. Combination Warfarin-ASA Therapy: Which Patients Should Receive It, Which Patients Should Not, And Why?. *Thrombosis Research*. Vol. 127 P. 513-517
- Firdaus, Isman, 2007. Fibrilasi Atrium Pada Penyakit Hipertiroidisme: Patogenesis dan Tatalaksana. *Jurnal Kardiologi Indonesia*. Jakarta Vol. 28 No. 5 P. 375-386
- Fox, K. A. A., White, H. D., Gersh, B. J., Opie, L. H., 2013. Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In: Opie, L. H., Gersh, B. J. *Drugs For The Heart*. Philadelphia: Elsevier Saunders. Vol. 8 P. 356-362.
- Georgiopoulou, V.V., Kalogeropoulos, A.P., Raggi, P., Butler, J., 2010. Prevention, Diagnosis, and Treatment of Hypertensive Heart Disease. *Cardiology Clinic*. Vol. 28 P. 675-591
- Harter, K., Levine, M., and Henderson, S. O., 2015. Anticoagulation Drug Therapy. *Western Journal of Emergency Medicine : Integrating Emergency Care With Population Health*. California. Vol. 16 No. 1 P. 11-17
- Hendriks, J., and Heidbüchel, H., 2018. The Management of Atrial Fibrillation. *European Journal of Cardiovascular Nursing*. P. 1-8
- Herman, R. B., 2010. *Buku Ajar Fisiologi Jantung*. Jakarta: EGC. P. 1-37
- Holm, J., Lindh, J. D., Andersson, M. L., Mannheimer, B., 2017. The Effect of Amiodarone on Warfarin Anticoagulation: A Register-Based Nationwide Cohort Study Involving The Swedish Population. *Journal of Thrombosis Haemostasis*. Vol. 15 No. 3 P. 446-453

- Katzung, B. G., Masters, S. B., Trevor, A., 2012. *Basic and Clinical Pharmacologi 12 Edition*. P 608-611
- Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H. C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Popescu, B. A., Schotten, U., Putte, B. V., Vardas, P., 2016. Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. *European Heart Journal*. Vol. 37 P. 2893-2962
- Kumar, D. R., Hanlin, E. R., Glurich, I., Mazza, J. J., Yale, S. H., 2010. Virchow's Contribution to the Understanding of Thrombosis and Cellular Biology. *Clinical Medicine & Research*. Vol. 8 No. 3/4 P. 168-172
- Lane, D.A., and Lip, G.Y.H., 2012. Use of The CHA₂DS₂ – VASc and HAS-BLED Scores to Aid Decision Making for Thrombophylaxis in Nonvalvular Atrial Fibrillation. *American Heart Association*. Vol. 126 P. 860-865
- Lau, Y. F., Yiu, K. H., Tse, H. F., 2012. Hypertension and Atrial Fibrillation: Epidemiology, Pathophysiology, and Therapeutic Implications. *Journal Of Human Hypertension*. Vol. 26 P. 563 - 569
- Magnani, J. W., Rienstra, M., Lin, H., Sinner, M. F., Lubitz, S. A., Mcmanus, D. D., Dupuis, J., Ellinor, P. T., and Benjamin, E. J., 2011. Atrial Fibrillation: Current Knowledge and Future Direction in Epidemiology and Genomics. *American Heart Association*. Vol. 124 P. 1982-1993
- Martinez, C., Katholing, A., Freedman, S. B., 2014. Adverse Prognosis of Incidentally Detected Ambulatory Atrial Fibrillation. *Blood*

Coagulation, Fibrinolysis, and Cellular Haemostasis. Vol. 112
NO. 2 P. 276-286

Martins, M. A. P., Reis, A. M. M., Sales, M. F., Nobre, V., Riberio, D, D.,
Rocha, M. O. C., Ribeiro, A. L. P., 2013. Rifampicin-Warfarin
Interaction Leading to Microscopic Hematuria: a Case Report and
Review of the Literature. *BMC Pharmacology and Toxicology*. P.
1-5

McEvoy, G. K., 2011. *AHFS Drug Information*. Bethesda: American
Society of Health-System Pharmacist

Minno, A. D., Frigerio, B., Spadarella, G., Ravani, A., Sansaro, D., Amato,
M., Kitzmiller, J. P., Pepi, M., Tremoli, E., Baldassarre, D., 2017.
Old and New Oral Anticoagulant: Food, Herbal Medicines, and
Drug Interactions. *Blood Review*. Vol. 2 No. 1 P. 1-11

Motloch, L. J., Reda, S., Larbig, R., Wolff, A., Motloch, K. A., Wernly, B.,
Granitz, C., Lichtenauer, M., Wolny, M., Hoppe, U. C., 2017.
Characteristics Of Coronary Artery Disease Among Patients With
Atrial Fibrillation Compared To Patients With Sinus Rhythm.
Hellenic Journal of Cardiology. Vol. 58 No. 3 P. 204-212

Natale, Andrea, 2008. *Atrial Fibrillation from Bench to Bedside*. USA :
Human Press, P. 3-6 : 178-179

Palm, F., Urbanek, C., Wolf, J., Buggle, F., Kleeman, T., Hennerici, M.G.,
Inselmann, G., Hagar, M., Safer, A., Becher, H., Grau, A.J., 2012.
Etiology, Risk Factors and Sex Differences in Ischemic Stroke in
the Ludwigshafen Stroke Study, a Population-Based Stroke
Registry. *Cerebrovascular Disease*. Vol. 33 P. 69-75

Purba, B. A., 2013. *Fisiologi Kardiovaskular*. Jambi. P. 12

- Redman, A. R., Zheng, J., Shamsi, S. A., Huo, J., Kelly, E. J., Ho, R. J. Y., Ritchie, D. M., Hon, Y. Y., 2008. Variant CYP2C9 Allels and Warfarin Concentration in Patients Receiving Low-Dose Versus Average-Dose Warfarin Therapy. *Clinical and Applied Thrombosis/ Hemostasis*. Vol. 14 No. 1 P. 29-37
- Republik Indonesia, 2016. Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Rumah Sakit. Jakarta
- Romley J.A., Gong C., Jena A.B., William B., And Peters A., 2015. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events : retrospective cohort studies. *BMJ*. Vol. 351 P. 1-8
- Ronald Reagan UCLA Medical Center. 2008. *Anticoagulant Management Program and Guidelines*. P. 1-16
- Sahay, R.N., Salagre, K.D., Dedhia, K.R., 2017. Study of Environmental and Genetic Factors Determining Warfarin Toxicity. *International Journal of Research in Medical Sciences*. Vol. 5 No.2 P. 463-468
- Schdeva, P. D. and Patel, B.G., 2010. Drug Utilization Studies-Scope And Future Perspectives. *International Journal on Pharmaceutical and Biological Research* Volume 1, P. 11- 17
- Schmidt, Constanze, 2011. The Pathology and Treatment of Cardiac Arrhythmias: Factor on Atrial Fibrillation. *Valvular Health and Risk Management*. Vol. 7 P. 194.
- Shaik, A.N., Bohnert, T., Williams, D.A., Gan, L.L., and LeDuc, B.W., 2016. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. *Journal of Pharmaceutical Sciences*. Vol. 30 P. 1-11

- Shalini, S., Ravichandran, V., Mohanty, B.K., Dhanaraj, S.K., and Saraswathi, R., 2010. Drug Utilization Studies – An Overview. *International Journal of Pharmaceutical Sciences and Nanotechnology*. Vol. 3 No. 1, p. 805
- Shikdar, Sufana, and Bhattacharya, P. T., 2019. *International Normalized Ratio (INR)*. Treasure Island (FL) : StatPearls. P. 1-10
- Shirayama, T., Shiraishi, H., Kuroyanagi, A., Hamaoka, T., Imai, M., Kojima, A., 2014. Interaction Between Warfarin and Proton Pump Inhibitor. *International Journal of Clinical Medicine*. Vol. 5 P. 836-843
- Singh, M., Adigopula, S., Patel, P., Kiran, K., Khosla, S., 2010. Recent Advances In Oral Anticoagulation For Atrial Fibrillation. *Therapeutic Advances in Oral Cardiovascular Disease*. Chicago. Vol. 4 No. 6 P. 395-407
- Sudarta, I. W., 2013. *Asuhan Keperawatan Klien dengan Gangguan Kardiovaskular*. Gosyen Publish: Yogyakarta, P. 1-12
- Suh, D. C., Nelson, W. W., Choi, J. C., Choi, I., 2012. Risk of Hemorrhage and Treatment Costs Associated With Warfarin Drug Interaction in Patients With Atrial Fibrillation. *Clinical Therapeutics*. Vol. 34 No. 7, P. 1569-1582
- Sweetman, S. C., 2009. *Martindale, the complete drug reference 36th*. London: The Pharmaceutical Press. P. 1425-1433
- Tadic, M., Cuspidi, C., 2015. Type 2 Diabetes Mellitus and Atrial Fibrillation : From Mechanism to Clinical Practice. *Elsevier Masson France*. Vol. 108 P. 269-276
- Weitz, J. I., 2008. Antiplatelet, Anticoagulant, and Fibrinolytic Drugs: Introduction *In*: A.S. Fauci, D. L. Kasper, D. L. Longo, E.

- Braunwald, S. L. Hauser, J. L. Jameson, J. Loscalzo (Eds.). ***Harrison's Principles of Internal Medicine***. New York: McGraw Hill Companies Inc. Chapter 118
- Whitaker, R. H., 2014. Anatomy of the Heart. ***Journal Medicine***. Vol. 42 No. 8 P. 406-408
- White, P. J., 2010. Patient Factors That Influence Warfarin Dose Response. ***Journal of Pharmacy Practice***. Vol.23 No.3 P.194-204
- White, C. M., Song, J. C., dan Kalus, J. S., 2009. ***Chapter 19: Cardiac Arrhythmia. Dalam: Applied Therapeutics: The Clinical Use of Drugs***. United States of America: Lippincott Williams & Wilkins.
- Witt, D. M., Delate, T., Clark, N. P., Martell, C., Tran, T., Crowther, M. A., Garcia, D. A., Ageno, W., Hylek, E. M., 2010. Twelve-month Outcomes and Predictors of very Stable INR Control in Prevalent Warfarin Users. ***Journal of Thrombosis and Haemostasis***. Vol. 8 P. 744-749
- Wongcharoen, W., Chen, S. A, 2012. The Pathophysiology of Atrial Fibrillation in Heart Failure. ***The Journal of Innovation in Cardiac Rhythm Management***. Vol. 3 P. 865-869
- Yansen, I., Yuniadi, Y., 2013. ***Tata Laksana Fibrilasi Atrium: Kontrol Irama atau Laju Jantung***. Vol. 40 No.3 P. 171-174
- Yuniadi, Y., Tondas, A. E., Hanafy, D. A., Hermanto, D. Y., Maharani, E., Munawar, M., Raharjo, S. B., 2014. ***Pedoman Tata Laksana Fibrilasi Atrium***. P. 31-58
- Zehnder, J. L., 2007. Drugs Used In Disorders of Coagulation. In: B. G. Katzung. ***Basic and Clinical Pharmacology***. Ed 10th, New York: McGraw Hill Companies Inc., P. 542-559

- Zhang, J., Wang, Y., Wang, G., Sun, H., Sun, T., Shi, J., Xiao, H., 2011. Clinical Factors in Patients With Ischemic Versus Hemorrhagic Stroke in East China. *World Journal of Emergency medicine*. Vol. 2 No.1 P. 18-23
- Zhang, Y., Dedkov, E. I., Teplitsky, D., Weltman, N. Y., Pol, C. J., Rajagopalan, V., Lee, B., gerdes, M., 2013. Both Hypothyroidism and Hyperthyroidism Increase Atrial Fibrillation Inducibility in Rats. *Circ Arrhythm Electrophysiol*. Vol. 6 P. 952-959
- Zimetbaum, P., Falk, R. H., 2013. Atrial Fibrillation. In: *Cardiovaskular Therapeutics A Companion to Braunwald's Heart Disease Fourth Ed*. Philadelphia: El Sevier Saunders. Vol. 111 P. 3150-3156.